Radiation therapy is the medical use of ionizing radiation to treat cancer. In conventional radiation therapy, beams of X rays (high energy photons) are produced by accelerated electrons and then delivered to the patient to destroy tumour cells. Using crossing beams from many angles, radiation oncologists irradiate the tumour target while trying to spare the surrounding normal tissues. Inevitably some radiation dose is always deposited in the healthy tissues.
When the irradiating beams are made of charged particles (protons and other ions, such as carbon), radiation therapy is called hadrontherapy. The strength of hadrontherapy lies in the unique physical and radiobiological properties of these particles; they can penetrate the tissues with little diffusion and deposit the maximum energy just before stopping. This allows a precise definition of the specific region to be irradiated. The peaked shape of the hadron energy deposition is called Bragg peak and has become the symbol of hadrontherapy. With the use of hadrons the tumour can be irradiated while the damage to healthy tissues is less than with X-rays.
The idea of using protons for cancer treatment was first proposed in 1946 by the physicist Robert Wilson, who later became the founder and first director of the Fermi National Accelerator Laboratory (Fermilab) near Chicago. The first patients were treated in the 1950s in nuclear physics research facilities by means of non-dedicated accelerators. Initially, the clinical applications were limited to few parts of the body, as accelerators were not powerful enough to allow protons to penetrate deep in the tissues.
In the late 1970s improvements in accelerator technology, coupled with advances in medical imaging and computing, made proton therapy a viable option for routine medical applications. However, it has only been since the beginning of the 1990s that proton facilities have been established in clinical settings, the first one being in Loma Linda, USA. Currrently about thirty proton centres are either in operation or in construction worldwide.
The global Hadron Therapy market was valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Hadron Therapy volume and value at global level, regional level and company level. From a global perspective, this report represents overall Hadron Therapy market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Hadron Therapy in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Hadron Therapy manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.
The following manufacturers are covered:
Koninklijke Philips N.V.
Advanced Oncotherapy
Varian Medical Systems
Optivus Proton Therapy
Hitachi, Ltd.
Mevion Medical Systems
ProTom International
Mitsubishi Electric Corporation
Sumitomo Corporation
ProNova Solutions, LLC
Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India
Segment by Type
Electron Beam
Proton Beam
Neutron Beam
Carbon Ion Beam
Alpha Particle Beam
Beta Particle Beam
Segment by Application
Pediatric Cancer
Bone and Soft Tissue Cancer
Prostate Cancer
Lung Cancer
Liver Cancer
Eye Cancer
Head & Neck Cancer
Others Applications (Renal Cell Carcinoma, Cervical, Gastric, and Lymphoma)
Summary:
Get latest Market Research Reports on Hadron Therapy. Industry analysis & Market Report on Hadron Therapy is a syndicated market report, published as Global Hadron Therapy Market Professional Survey Report 2019. It is complete Research Study and Industry Analysis of Hadron Therapy market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.